Japanese pharmaceutical company Eisai is set to open a new exploratory research facility in Cambridge, Massachusetts, US, to identify new drugs for the treatment of dementia.

The Eisai Center for Genetics Guided Dementia Discovery (G2D2) will primarily work on an immuno-dementia drug discovery approach with focus on regulating neural inflammation, a primary cause of the disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

G2D2 will build its research on human genetics, neuro- and immune-biology, and precision chemistry discerned by the Andover innovative Medicines (AiM) Institute situated in Massachusetts.

The new facility intends to carry out functional genetic analysis of dementia and focus on different proteins that are expressed on microglia as targets for drug discovery. The partners hope to introduce a compound discovered via the immuno-dementia research into the clinic by 2020.

Eisai plans to begin operations at G2D2 during the first quarter of its fiscal 2019 with around 70 employees. The centre will be led by AiM Institute president Nadeem Sarwar and that institute will be closed after the new facility becomes operational.

The company also plans to set up a research space at G2D2 that will open to external organisations and outstanding researchers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, Eisai hopes to advance drug discovery through G2D2’s focus on human genetics along with the European Knowledge Center in the UK run for open innovation drug discovery via partnerships with local academia, and KAN Research Institute (Kobe) working on synapse micro-environment.

The pharmaceutical firm is also accelerating organic partnership with the Eisai-Keio Innovation Lab for Dementia to carry out exploratory research for treatments using a multi-dimensional, comprehensive technique.